Casual Friday Series

Crohn's Disease Part 3

A Biogenetix Clinical Presentation BIOGENETIX.COM




Disclaimer

- Information in this presentation is not intended to diagnose, treat, reverse, cure, or prevent any disease. While this presentation is based on medical literature, findings, and text, The following statements have not been evaluated by the FDA.
- The information provided in this presentation is for your consideration only as a practicing health care provider. Ultimately you are responsible for exercising professional judgment in the care of your own patients.




CROHN'S DISEASE

PATCHY INFLAMMATION THROUGHOUT SMALLAND LARGE BOWEL




ULCERATIVE COLITIS

CONTINUOUS AND UNIFORM INFLAMMATIONIN THE LARGE BOWEL













Stool tests to rule out infections include culture and sensitivities, ovum and parasites, Clostridium difficile toxins, leukocyte count. Stools for calprotectin can detect active Crohn disease and are also used for monitoring disease. [12] [13][14][15]

Blood tests including complete blood count and a metabolic panel can highlight the presence of anemia (B12 or iron deficiency) or liver disease. Special serology such as normal anti-neutrophil cytoplasmic antibodies (ANCA) and raised anti-saccharomyces cerevisiae antibodies (ASCA) can distinguish Crohn disease from ulcerative colitis. Creactive protein (CRP) or erythrocyte sedimentary rate (ESR) can reflect the severity of the inflammation.

influenza, pneumococcal, hepatitis A, hepatitis B, measles, mumps, rubella, varicella-zoster virus) should be known, if no prior history titers of hepatitis A, hepatitis B, measles, mumps, rubella, and the varicella-zoster virus should be checked. Baseline Mantoux test with chest radiograph should also be checked before any treatment. Baseline thiopurine methyltransferase (TPMT) levels should be checked before deciding on treatment options. Low levels of TMPT may result in an increased risk of side effects, whereas very high levels may decrease the effectiveness of prescribed treatment.







Inflamm Bowel Dis. 2017 Nov; 23(11): 2054-2060.

Published online 2017 Aug 29. doi: 10.1097/MIB.000000000001221

PMCID: PMC5647120

NIHMSID: NIHMS889275

PMID: 28858071

Efficacy of the Autoimmune Protocol Diet for Inflammatory Bowel Disease

Anita C

Author

Despite diet being implicated in the pathogenesis of IBD,⁴ we have limited data to guide the use of nutritional therapy as either primary or adjunctive treatment for these conditions. Conventional medical therapy for IBD focuses on suppression of the immune system by targeting a variety of pathways, yet response rates continue to remain suboptimal. Therefore, there is an important need to study dietary factors that may not only help improve response to conventional treatment but also potentially be used as primary therapy or maintenance therapy for patients with IBD. A Western diet, high in refined carbohydrates, omega-6 fatty acids, saturated fat, low in fiber, vitamins, and generally nutrient dense foods, are associated with an increased risk of IBD.⁴ Recent albeit limited data suggest that a semivegetarian diet⁵ (allowing milk and eggs, fish once per week, and other meat once every 2 weeks), specific carbohydrate diet⁶⁻⁸ (removal of all grains, most dairy products, and sweeteners except for honey), or anti-inflammatory diet⁹ (modified carbohydrate and fatty acid intake, and increased prebiotic/probiotic ingestion) can be associated with improved rates of achieving or maintaining clinical response.

The autoimmune protocol (AIP) diet is an extension of the Paleolithic diet¹⁰ and incorporates some of the dietary changes previously studied in IBD, including avoidance of gluten and refined sugar. The AIP diet focuses on an initial elimination phase of food groups including grains, legumes, nightshades, dairy, eggs, coffee, alcohol, nuts and seeds, refined/processed sugars, oils, and food additives. ^{10,11} The rationale is to avoid foods, additives, or medications (e.g., nonsteroidal anti-inflammatory drugs) that can trigger intestinal inflammation, dysbiosis, and/or symptomatic food intolerance. ^{10,12–14} It also emphasizes consumption and preparation of fresh, nutrient dense foods, bone broth, and fermented foods, while addressing factors that are known to associate with disability due to IBD, such as sleep and sleep hygiene, stress management, forming a support system, and physical activity. ¹⁵ The elimination phase is followed by a maintenance phase, the duration of which can vary by individual, until they achieve a measurable improvement in their symptoms and overall well-being. Staged reintroduction of food groups is then initiated gradually, as patients identify unique foods or food groups that may contribute to symptoms while liberalizing their diet. ^{10,11}



Published online 2017 Aug 29. doi: 10.1097/MIB.000000000001221

PMCID: PMC5647120

NIHMSID: NIHMS889275

PMID: 28858071

Efficiency of the Autoimmune Protocol Diet for Inflammatory Down Disease

TABLE 3.

Effect of AIP Diet on Fecal and Serum IBD Biomarkers


Week 0 versus 6 Results	n	Week 0	Week 6	P
FC (μg/g), mean (SD)	8	267 (367)	157 (251)	0.45
Baseline FC $>$ 50 μ g/g, mean (SD)	5	412 (406)	196 (317)	0.36
CRP (mg/L), mean (SD)	11	8.3 (11.5)	7.0 (14.5)	0.46
Albumin (g/dL), mean (SD)	11	3.9 (0.4)	3.9 (0.4)	0.82
Week 0 versus 11 Results	n	Week 0	Week 11	P
FC (μg/g), mean (SD)	6	471 (562)	112 (104)	0.12
Baseline FC $>$ 50 μ g/g, mean (SD)	4	701 (563)	139 (113)	0.09
CRP (mg/L), mean (SD)	9	3.9 (5.2)	3.4 (5.3)	0.82
(mg/2), mean (52)				

(76% Reduction)



46 yo male, current diagnosis and brief hx:

- Fatigue, blurry vision, insomnia, gi/inguinal abscesses, ED
- DM2
- Depression
- GERD
- Hairy-cell leukemia, experimental chemo
- Family hx of NAFLD, Alz, DM2, Cx





	Test	Current Resu	ılt and Flag	Previous Result and Date	Units	Reference Interva
	Chemistries 01					
1	Glucose 01	133		eptember 26, 2022 Glucose ro ll be changing to:		65-99
					70 - 99	
1	Hemoglobin A1c 01	11.5	High		%	4.8-5.6
	Please Note: 01	Diabet	abetes: 5.7 - tes: >6.4 nic control fo	6.4 r adults with diabetes: <7.0	a	
	Uric Acid 01	3.9	Th	erapeutic target for gout pa	mg/dL atients: <6.0	2.6-6.2
	BUN ⁰¹	12			mg/dL	6-24
A	Creatinine 01	1.05	High		mg/dL	0.57-1.00
	eGFR	66			mL/min/1.73	>59
	BUN/Creatinine Ratio	11				9-23
	Sodium 01	137			mmol/L	134-144
	Potassium 01	3.9			mmol/L	3.5-5.2
	Chloride 01	100			mmol/L	96-106
	Carbon Dioxide, Total 01	22			mmol/L	20-29
	Calcium 01	9.5			mg/dL	8.7-10.2
	Phosphorus 01	3.4			mg/dL	3.0-4.3
	Magnesium 01	1.8			mg/dL	1.6-2.3
	Protein, Total 01	7.1			g/dL	6.0-8.5
	Albumin 01	3.9			g/dL	3.8-4.8
	Globulin, Total	3.2			g/dL	1.5-4.5
	A/G Ratio	1.2				1.2-2.2
	Bilirubin, Total ⁰¹	0.4			mg/dL	0.0-1.2
	Alkaline Phosphatase 01	102			IU/L	44-121
	LDH 01	124			IU/L	119-226
A	AST (SGOT) 01	48	High		IU/L	0-40
1	ALT (SGPT) 01	50	High		IU/L	0-32
	GGT 01	59			IU/L	0-60



	Ferritin 01	545	High	ng/mL	15-150
A	Cholesterol, Total 01	231	High	mg/dL	100-199
	Triglycerides 01	619	Alert	mg/dL	0-149
•	HDL Cholesterol 01	24	Low	mg/dL	>39
_	VLDL Cholesterol Cal	106	High	mg/dL	5-40
_	LDL Chol Calc (NIH)	101	High	mg/dL	0-99
A	T. Chol/HDL Ratio	9.6	High	ratio	0.0-4.4
		/ 111 - 11-4	1 1		



	Homocyst(e)ine 01	7.5			umol/L	0.0-14.5
•	TSH 01	5.390	High		uIU/mL	0.450-4.500
S	Thyroxine (T4) 01	8.2			ug/dL	4.5-12.0
	T3 Uptake 01	29			%	24-39
	Free Thyroxine Index	2.4				1.2-4.9
	Triiodothyronine (T3) 01	108			ng/dL	71-180
	Triiodothyronine (T3), Free 01	2.7			pg/mL	2.0-4.4
0	Reverse T3, Serum ^{A, 02}	21.7			ng/dL	9.2-24.1
	T4,Free(Direct) 01	1.26			ng/dL	0.82-1.77
	Thyroid Peroxidase (TPO) Ab 01	<8			IU/mL	0-34
	Thyroglobulin Antibody 01	<1.0 Thyroglobulin A	ntibody measu	red by Beckman Coulter Methodol	IU/mL ogy	0.0-0.9
•	Vitamin D, 25-Hydroxy ⁰¹	Medicine and an level of serum The Endocrine S insufficiency a 1. IOM (Institution in takes for National Aca 2. Holick MF, B Evaluation, deficiency:	Endocrine So 25-OH vitamin ociety went os a level bet te of Medicin calcium and D demies Press. inkley NC, Bitreatment, an an Endocrine	n defined by the Institute of ciety practice guideline as a D less than 20 ng/mL (1,2). In to further define vitamin D ween 21 and 29 ng/mL (2). e). 2010. Dietary reference Dietary	ng/mL	30.0-100.0




29.6		pg	26.6-33.0
33.0		g/dL	31.5-35.7
14.2		%	11.7-15.4
171		x10E3/uL	150-450
26		%	Not Estab.
67		%	Not Estab.
5		%	Not Estab.
2		%	Not Estab.
0		%	Not Estab.
1.7		x10E3/uL	1.4-7.0
4.5	High	x10E3/uL	0.7-3.1
0.3		x10E3/uL	0.1-0.9
0.1		x10E3/uL	0.0-0.4
0.0		x10E3/uL	0.0-0.2
0		%	Not Estab.
0.0		x10E3/uL	0.0-0.1
6.7		x10E3/uL	3.4-10.8
4.77		x10E6/uL	3.77-5.28
14.1		g/dL	11.1-15.9
42.7		%	34.0-46.6
90		fL	79-97
	33.0 14.2 171 26 67 5 2 0 1.7 4.5 0.3 0.1 0.0 0 0.0 6.7 4.77 14.1 42.7	33.0 14.2 171 26 67 5 2 0 1.7 4.5 High 0.3 0.1 0.0 0 0.0 6.7 4.77 14.1 42.7	33.0 g/dL 14.2 % 171 x10E3/uL 26 % 67 % 5 % 0 % 1.7 x10E3/uL 4.5 High x10E3/uL 0.3 x10E3/uL 0.0 x10E3/uL 0.0 x10E3/uL 0.1 x10E3/uL 0.0 x10E3/uL 0.0 x10E3/uL 0.0 x10E3/uL 0.0 x10E3/uL 0.0 y6 1.7 x10E3/uL 0.0 y6 0.0 x10E3/uL




:-Peptide, Serum				
Test	Current Result and	Flag Previous Result and Date	Units	Reference Interval
C-Peptide, Serum 01	2.7		ng/mL	1.1-4.4
10 VIII (1900) 10 VIII (1900)	C-Peptide reference	interval is for fasting patients.	1000	
nsulin				
Test	Current Result and	Flag Previous Result and Date	Units	Reference Interval
▲ Insulin ⁰¹	42.0	High	uIU/mL	2.6-24.9




Dutch Test






Testo	Testosterone						
Age	Range						
18-25	50-115						
26-40	40-95						
41-60	30-80						
>60	25-60						

Adrenal Hormones See pages 4 and 5 for a more complete breakdown of adrenal hormones






Free cortisol best reflects tissue levels. Metabolized cortisol best reflects total cortisol production.



Dutch Test

Category	Test	100 mm 150 mm	Result	Units	Normal Range		
	Nut	tritional Organic Acid	ls				
Vitamin B12	Marker (may be deficient if high)	- (Urine)					
	Methylmalonate (MMA)	Within range	2.58	ug/mg	0 - 3.5		
Vitamin B6 M	arkers (may be deficient if high)	- (Urine)					
	Xanthurenate	Within range	0.54	ug/mg	0.2 - 1.9		
	Kynurenate	Within range	2.02	ug/mg	1 - 6.6		
Glutathione N	larker (may be deficient if low or	high) - (Urine)					
	Pyroglutamate	Below range	32.3	ug/mg	38 - 83		
Biotin Marker	Biotin Marker (may be deficient if high) - (Urine)						
	b-Hydroxyisovalerate	Within range	13.2	ug/mg	0 - 18		
Gut Marker (p	potential gut putrefaction or dysl	oiosis if high) - (Urine)					
	Indican	Within range	106.1	ug/mg	0 - 131		
	Ne	euro-related Markers					
Dopamine Me	etabolite - (Urine)						
	Homovanillate (HVA)	Below range	3.4	ug/mg	4 - 16		
Norepinephri	ne/Epinephrine Metabolite - (Urir	ne)					
	Vanilmandelate (VMA)	Low end of range	2.6	ug/mg	2.5 - 7.5		
Neuroinflamn	nation Marker - (Urine)	Lauridau III. II. II. II. II. I					
	Quinolinate	Within range	6.8	ug/mg	0 - 12.5		
		Additional Markers					
Melatonin (*n	neasured as 6-OH-Melatonin-Su	lfate) - (Urine)					
		Low end of range	18.4	ng/mg	10 - 85		
Oxidative Str	ess / DNA Damage, measured a	s 8-Hydroxy-2-deoxygu	anosine (8	-OHdG) -	(Urine)		
	8-OHdG (Waking)	Within range	2.39	ng/mg	0 - 8.8		





Stool Sample Doctor's Data

	BACTERIOLOGY CULTURE	
Expected/Beneficial flora	Commensal (Imbalanced) flora	Dysbiotic flora
3+ Bacteroides fragilis group	2+ Klebsiella pneumoniae/variicola	3+ Citrobacter freundii complex
2+ Bifidobacterium spp.	2+ Rothia dentocariosa	3+ Citrobacter freundii complex,isolate 2
NG Escherichia coli	3+ Streptococcus anginosus	
2+ Lactobacillus spp.	3+ Streptococcus salivarius	
NG Enterococcus spp.	2+ Streptococcus agalactiae (Beta strep,	
2+ Clostridium spp.	group B)	
NG = No Growth		



Stool Sample Doctor's Data

Digestion / Absorption	Result	Unit		Reference Interval
Elastase	60	μg/g		> 200
Fat Stain	Not Detected			None – Moderate
Carbohydrates [†]	Negative			Negative
nflammation	Result	Unit		Reference Interval
Lactoferrin	11.8	μg/mL		< 7.3
Calprotectin	276	μg/g		< 80
Lysozyme*	342	ng/mL		≤500
mmunology	Result	Unit	5 5 5 5	Reference Interval
Secretory IgA*	0.7	mg/dL		30-275
Short Chain Fatty Acids	Result	Unit		Reference Interval
% Acetate [‡]	57	%		50-72
% Propionate [‡]	25	%		11 – 25
% Butyrate [‡]	13	%		11 – 32
% Valerate‡	6.2	%		0.8 - 5.0
Butyrate [‡]	0.83	mg/mL		0.8-4.0
Total SCFA's‡	6.5	mg/mL		5.0 – 16.0
ntestinal Health Markers	Result	Unit	2 1 2 2 2	Reference Interval
ρΗ	6.5			5.8-7.0
Occult Blood	Positive			Negative
Macroscopic Appearance	Result	Unit		Reference Interval
Color	Brown			Brown
Consistency	Soft			Soft



